Trials / No Longer Available
No Longer AvailableNCT03544060
Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
Volanesorsen (ISIS 304801) Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Akcea Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this program is to provide expanded access to volanesorsen for up to 100 Patients with Familial Chylomicronemia Syndrome (FCS).
Detailed description
The Program is intended to provide expanded access to volanesorsen for eligible patients with FCS who have limited or no available treatment options.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Volanesorsen | Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm. |
Timeline
- First posted
- 2018-06-01
- Last updated
- 2021-09-16
Source: ClinicalTrials.gov record NCT03544060. Inclusion in this directory is not an endorsement.